In targeted therapy, nanoparticles carrying tyrosine kinase inhibitors (TKIs, such as icotinib or erlotinib) can specifically inhibit signaling pathways driven by EGFR or BRAF mutations, while simultaneously sensitizing tumor cells to ferroptosis inducers (61, 62). Here, BRAF is linked to neoplasm.